Molecular Devices and STEMCELL automate an intestinal organoid workflow

Molecular Devices and STEMCELL Technologies have released an automated workflow for growing and monitoring human intestinal organoids. The protocol combines STEMCELL's IntestiCult Plus Organoid Growth Medium with Molecular Devices' CellXpress.ai Automated Cell Culture System.

What has been announced

The companies describe the workflow as validated for automated culture of human intestinal organoids and have made the protocol available for download. It is the first deliverable in a broader collaboration intended to automate additional STEMCELL organoid kits.

CellXpress.ai is positioned as an integrated system for culture, liquid handling, imaging and analysis. Bringing a commercial medium and a defined automation sequence together could reduce manual interventions and give laboratories a more transferable starting point than a locally assembled robotics workflow.

Why it matters

Organoid biology often advances faster than organoid operations. Feeding schedules, matrix handling, imaging and passage decisions demand skilled labour, while subtle operator differences can accumulate into batch effects. Automation is valuable when it makes those actions explicit, logged and repeatable—not simply when it increases throughput.

An intestinal workflow is a meaningful test case because organoids must be maintained as living, changing structures rather than treated as static assay wells. A robust system needs to manage culture health while producing images and metadata that support timely decisions.

What to watch

“Validated” here describes a vendor-developed workflow. The important next evidence will be performance across donor sources, operators and independent sites, together with comparison against expert manual culture. Users will also want clarity on passage recovery, phenotype stability, cost per usable organoid and compatibility with downstream screening.

The collaboration becomes more consequential if future workflows share data structures and quality criteria across tissues. A collection of isolated automation recipes is useful; a common operational framework for organoid manufacture would be more powerful.

HCMX take

This is infrastructure rather than a new biological model, but infrastructure is exactly where many organoid programmes stall. The strongest outcome would be a workflow that makes variance visible and manageable while preserving the biological complexity researchers adopted organoids to study.